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Details of analytic techniques 
MAPK Assay Peripheral Blood Mononuclear Cells (PBMCs) were isolated from 10ml 
venous blood samples and spun into freeze-dried cell pellets (Manchester Biobank). 
Dried cell pellets were shipped with dry ice to UCLA for analysis using western blot 
electrophoresis. Protein concentration was determined using a BCA assay kit and 
equal amounts of proteins (10 ug) were separated by electrophoresis on 4-12% SDS-
PAGE gels. After transferring to nitrocellulose membrane, membranes were blocked 
with 5% BSA in TBS-T for 1 hour then hybridized with a primary antibody (p-
MAPK) overnight at 40C. After washing with TBS-T, the membrane was incubated 
with a secondary antibody in 5% nonfat milk and TBS-T for 1 hour. Signals were 
visualized by ECL. After detecting p-MAPK, the membranes were striped and re-
probed with a total MAPK antibody. The total MAPK were used to normalize with 
each sample. The following primary antibodies were used: p-MAPK (#9101S, Cell 
Signaling, 1:1,000), anti-total MAPK (#9102S, Cell Signaling, 1:5,000)  
Imaging preparation Participating families were provided with a two-week imaging 
habituation protocol and an audio CD of study-specific scanner noise. The patient 
cohort was acclimatised to awake MRI scanning using a social story preparation and 
two weeks of graded exposure to mp3 recordings of the sounds made by the MRI 
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scanner. This was initially at any time of the day, then specifically at bedtime. These 
recordings were prioritised in the same order as each specific scan sequence in the 
imaging protocol. Children and families were assisted through the scanning procedure 
with a clinical protocol led by a play specialist, clinical nurses and psychiatrists.  
 
Details of imaging protocol 
Table S1: MRI sequence parameters and scan time duration for a complete imaging 
acquisition lasting approximately 45 minutes*  
Sequence 
Order 
Sequence Name Duration 
(min) 
Parameters  
1 Resting State fMRI with Echo 
planar imaging (EPI) readout 
8.25 FOV 224mm, slice thickness 3mm, 
Slices 42, TE 35ms, TR 3000ms, 
Flip angle 90o degrees, number of 
dynamic scans 160, acq matrix 
80×76, recon matrix 80. 
2 T1 Inversion-recovery fast 
gradient echo 3-D volume 
5.75 FOV 240mm, Voxel size 
1x1x1mm3, TR 6.9ms, TE 3.2ms, 
flip angle 9o, acq matrix 240×188, 
recon matrix 240. 
3 T2 Axial Turbo Spin Echo 1.77 FOV 230mm, Slice thickness 
4mm, slices 28, slice gap 1mm, TE 
80ms, TR 3000ms, acq matrix 
400×255, recon matrix 512. 
4 Diffusion Tensor Imaging with 
EPI readout 
1.87 FOV 230mm, Slice thickness 
2.5mm, slices 55, b value 0 and 
1000 smm-2, Directions 6, TR 
5353ms, TE 73ms, slice gap 0, acq 
matrix 112×86, recon matrix 128. 
5 Arterial Spin Labelling with EPI 
readout 
5.5 Labelling Slab 150mm, with a gap 
of 15mm and increasing delay 
times from 600 ms to 3050 ms - 
constant interval of 350 ms. Flip 
angle 40°; 3.5 × 3.5 × 6 mm3 
voxels with a 1 mm gap between 
slices; 15 slices covering the 
cerebrum, TR 3500ms, TE 11ms, 
acq matrix 64×61, recon matrix 64. 
6 GABA spectroscopy Frontal 
White Matter  
8.87  Single Voxel MEGA-PRESS, 
voxel size 3x3x3cm3, TR 2000ms, 
TE 68ms, 44 blocks of 4 averages, 
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interleaving decoupling and control 
MEGA pulses. 
7 GABA spectroscopy Deep Grey 
Nuclei 
8.87 As per 6  
* includes scout sequences, planning and time for shim. GABA spectroscopy for sequence 6 and 7 
related to differing voxel positioning. 
 
 
 
GABA Spectroscopy GABA was measured in two voxels of the brain; i) frontal white 
matter (FWM) and ii) deep grey nuclei (DGN) using the localized spectroscopy 
sequence MEGA-PRESS,[1] in which the dominant signal from creatine + 
phosphocreatine at 3.03 ppm, which overlaps the GABA C4 signal at 3.02 ppm, is 
suppressed by spectroscopic editing (Fig 1). The resultant edited spectrum consists of 
signals from glutamate and glutamine centred at 3.78 ppm (Glx), GABA at 3.02 ppm 
and an inverted signal from N-acetyl aspartate (NAA) at 2.02 ppm. For signal 
quantification, the AMARES algorithm implemented in jMRUI software[2] was 
utilized to calculate the concentrations of  GABA+ (consisting mainly of GABA but 
with contributions from co-edited macro-molecule signals), the sum of glutamate plus 
glutamine (Glx) and NAA. The AMARES approach is a prior-knowledge based 
quantification method in the time domain, applied via nonlinear least square fitting. 
Regarding voxel localization, in order to maximize the signal to noise ratio in these 
studies we faced a necessary trade-off between the size of the voxel that could be 
interrogated against the time taken in the scanner to acquire the spectroscopic data. 
Our preliminary work when designing the study indicated that the best trade off was a 
3cm x 3cm x 3cm voxel of interest which returned usable signal after an 8 minute 
acquisition. . Since we would not have been able to specifically acquire GABA data 
solely from the cortex given the lack of signal, we enlarged the interrogation voxel to 
that described above, and by necessity this would concentrate signal returen 
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fromconcentrate the frontal white matter.  Given previous studies have used similar 
voxel sizes [3, 4] and also concerntrated on the left frontal lobe in a similar region 
within the ASD population [3, 5, 6] we felt this voxel placement and size was 
appropriate[3, 4, 6]. 
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Figure S1 a) Spectrum obtained from 3x3x3 voxel placed in deep gray matter of a 5 
year old child using MEGA-PRESS suppression scheme at 3 T (top, non-edited sub-
spectrum; bottom, GABA-edited spectrum) showing signals from amino-acid protons 
(AA), choline-containing compounds (cho), creatine + phosphocreatine (cr), N-
acetylaspartate (NAA), GABA and glutamate + glutamine (glx). b) Figure depicting 
example output of AMARES Model fitting in jMRUI 
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The semi-automatic post-processing steps for metabolite quantification within each 
VOI (Fig 1) included manual averaging of spectra, removal of water peak using the 
Hankel-Lanczos Singular Value Decomposition filter,[7] reference the NAA peak to 
2.02 ppm, use of approximately 5 Hz apodization, and application of phase correction  
prior to jMRUI fitting. Prior knowledge on spectral parameters incorporated GABA+, 
which was modeled as a singlet with gaussian lineshape at 2.99 ppm, and glutamate 
plus glutamine (Glx), modeled as a doublet, with peaks at 3.71 and 3.78 ppm, and 
NAA set at 2 ppm as a single inverted Lorentzian peak. As contributions of 
macromolecules are expected when using MEGA-PRESS, the final quantification can 
only be described as GABA+ rather than GABA.  A similar procedure to the 
aforementioned was undertaken to quantify NAA and other metabolite 
concentrations. The reference spectrum, used to convert from model-based to absolute 
concentration, was the signal from the non-suppressed water voxel. Participant 
datasets were excluded from analysis if there was severe extracranial lipid 
contamination, motion-related artefacts or if the post-fitting assessment indicated that 
standard deviation of the amplitude was greater than a threshold of 30%. Exclusion 
was also made if there was significant NF1 related T2 signal hyperintensity in the 
proposed region of interest. Finally, a procedure was followed in order to overlay 
each acquired MRS voxel onto the corresponding T1 weighted image so as to correct 
for cerebrospinal fluid (CSF) contamination. The partial volume segmentation 
software that was used was created by Dr. Nia Goulden and Dr. Paul Mullins of 
Bangor University (https://www.bangor.ac.uk/psychology/biu/Wiki.php.en). The 
software generates a GM, WM and CSF image and calculates the percentages of the 
aforementioned tissue types within each MRS voxel. Statistical analyses were 
performed with SPSS version 22.0 (SPSS Inc., Chicago, IL). 
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Figure S2 Example locations of VOI (3x3x3 cm3) acquired from a) left fontal white 
matter and b) deep grey matter (including caudate, lentiform nucleus, thalamus and 
putamen)  
 
We considered both the absolute change in values of the various metrics measured in  
Table 1 from week zero to week twelve as well as the change in value of these 
features between the two time points, the null hypothesis being that if there was no 
effect of simvastatin on the brain then the distribution of changes should be the same 
between the two groups. This also allowed for the control of the wide variation in 
baseline measures. A student T-test was used for the absolute assessment of GABA 
values. With regards to the distribution of change two types of test were run. Firstly 
we ran an ANCOVA-type test, where an ordinary least-squares model of the form y = 
ax + bc was fit. Here x refers to the covariate of the initial value at week 0 and c refers 
to the group. Such a model makes normality and equal variance assumptions, 
therefore, we also applied the tests proposed by Vermeulen [8](a Mann-Whitney test 
with covariate adjustment) where the normality assumption is null. 
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Resting state fMRI Table S1 shows the parameters of the multi-slice whole brain 
acquisition of these data. Spatial networks demonstrating strong temporal coactivation 
in the resting BOLD fMRI responses were defined using probabilistic independent 
component analysis (ICA). Data analysis was performed using the FSL software 
library[9] with MELODIC ICA decomposition.[10] Preprocessing included motion 
correction for each 4D time series, [11] brain extraction, spatial smoothing (gaussian 
full-width half maximum 4 mm), high pass temporal filtering, and registration to an 
age-specific paediatric template (Cincinnati Children’s Hospital, Imaging Research 
Center, irc.cchmc.org). Identification and removal of motion related independent 
components was performed with ICA-AROMA.[12] Temporal concatenation group 
ICA decomposed the pre-processed data into 25 independent components, performed 
separately on data acquired at week zero and week twelve (n=21, n=17 respectively). 
The default mode network (DMN) was identified by the characteristic pattern of 
coactivation involving medial prefrontal, posterior cingulate/precuneus, lateral 
parietal, lateral temporal, and cerebellar regions.[13, 14] For comparison, 
sensorimotor and medial visual networks were identified by characteristic 
coactivation patterns including perirolandic and medial occipital regions 
respectively.[14] The analysis for differences between groups was performed using a 
dual regression technique which allowed for voxel-by-voxel comparisons of 
functional connectivity.[15] Briefly, this involved using the spatial group ICA maps 
to derive subject specific temporal responses and thus estimate subject specific spatial 
maps. Component maps from different subjects could then be compared between 
groups using non-parametric permutation testing (5,000 permutations). 
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Perfusion Imaging Perfusion imaging was achieved using arterial spin labelling 
(ASL). A pulsed STAR (signal targeting with alternating radiofrequency) labeling 
technique with Look-Locker readout[16] at eight timepoints was used for ASL-based 
perfusion imaging.[17] A series of excitation pulses were applied, with increasing 
delay times from 600 ms to 3050 ms, and a constant interval of 350 ms between them, 
followed by Look-Locker readout (TR/TE 350/11 ms,). To allow quantification of 
CBF a M0 (proton density) scan was acquired using a very similar multiphase ASL 
sequence but with TR of 10sec. The ASL analysis was carried out using in-house 
MATLAB (www.mathworks.com) routines. The raw images were qualitatively 
assessed for motion and artefacts before being processed with analysis using our 
previously published technique.[18] A single blood compartment model, was fit to the 
averaged images on a voxel-by-voxel basis, producing maps of Cerebral Blood Flow 
(CBF) and Arterial Arrival Time (AAT, without vascular crushing). Structural T1 
images were processed using FreeSurfer v5.3.0 using a standardized and 
automated pipeline - recon all - of cortical surface-based analysis.[19] The 
output of this analysis generated forty five separate regions of interest which 
were used to guide the calculation of regional perfusion values using the 
'Destrieux' cortical atlas [20] as per diffusion section. 
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Figure S3 Example illustrating in sagittal view the position of the perfusion-imaging 
slices, which were planned above the ventricles and the labelling slab (150 mm) that 
was set 10 mm below the imaging slices 
 
Diffusion Imaging The T1 images of each participant were preprocessed using the 
open source FreeSurfer v5.3.0 image analysis suite, which was downloaded and 
installed onto a Linux-based workstation.  The image analysis suite encompasses a set 
of CT computational tools, which provide a standardized and automated pipeline - 
recon all - of cortical surface-based analysis.[21] The output of the analysis was used 
to guide the calculation of regional ADC values. FSL v.5 software was used for 
preprocessing the raw diffusion MR datasets. Eddy current correction was applied to 
the data, using the appropriate tool via the FSL software; [9] this tool is used to 
correct eddy current induced distortions and simple head motion by affine registration 
to the b0 image. The median ADC value of each of the fourty five areas was 
calculated via registration of ADC maps to freesurfer output; this was computed via 
FLIRT. [11] 
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Judgement of Line Orientation (JLO) This test was used for assessment of 
visuospatial skills as reported in previous studies in NF1 cohorts. However, 
compliance with this test was low due to poor attentional skills and the younger age of 
the cohort. Due to these reasons and the amount of missing data, we do not report the 
results from this assessment.  
 
Table S2 Baseline Descriptive Data 
 Sample  
N=30 
Placebo  
N=16 
Simvastatin 
N=14 
Sex  
Male 
Female 
 
24 (80%) 
6 (20%) 
 
14 (87.5%) 
2 (12.5%) 
 
10 (71.4%) 
4 (28.6%) 
Mutation* 
Inherited 
De novo 
 
13 (43.3%) 
16 (53.3%) 
 
10 (62.5%) 
5 (31.3%) 
 
3 (21.4%) 
11 (71.4%) 
Age (years) 8.10 (1.80) 8.28 (1.76) 7.90 (1.90) 
Weight (kg) 27.88 (7.59) 29.85 (8.51) 25.76 (6.08) 
Social Responsiveness Scale (SRS) T 
Score (Mean, SD) 
83.00 (7.96) 83.06 (7.58) 82.93 (8.67) 
Autism Diagnostic Interview (ADI-R)    
Social Interaction (Total A) 17.67 (5.16) 18.88 (5.08) 16.29 (5.08) 
Social Communication (Total B) 14.10 (4.14) 14.19 (4.37) 14.00 (4.02) 
Restricted Repetitive Behaviours (Total 
C) 
5.90 (2.67) 5.88 (2.78) 5.93 (2.64) 
Autism Diagnostic Observation 
Schedule (ADOS)   
Social Affect 
RRB 
Total 
 
9.73(3.23) 
2.00(1.67) 
11.80(3.82) 
 
10.13(3.26) 
1.88(1.63) 
12.00(3.81) 
 
9.29 (3.24) 
2.14(1.74) 
11.57(3.96) 
WASI verbal IQ (n=26) 85.46 (12.72) 81.57 (12.99) 90.00 (11.24) 
Aberrant Behaviour Checklist (ABC) 
† 
   
Irritability 21.72 (10.03) 19.40 (10.38) 24.21 (9.36) 
Lethargy 15.07 (7.62)* 14.20 (8.36) 16.08 (6.85)* 
Stereotypy 6.03 (4.44) 4.87 (3.56) 7.29 (5.04) 
Hyperactivity 27.03 (11.42) 24.07 (13.04) 30.21 (8.75) 
Inappropriate speech 6.66 (3.40) 5.93 (3.15) 7.43 (3.61) 
Clinical Global Impression (CGI) 
Severity of Illness; mean (SD) 
3.73(0.785) 3.88 (0.885) 3.57(0.646) 
Parent-Defined Target symptoms     
Hyperactivity 13 6 7 
Aggression 13 6 7 
Social inappropriateness 18 9 9 
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Problems with communication 5 3 2 
Inflexibility/obsessionality 9 7 2 
Learning problems  3 1 2  
Conners 3 Parent Rating Scale†    
Inattention 80.21 (10.70) 79.73 (12.13) 80.71 (9.36) 
Hyperactivity 76.34 (12.95) 71.87 (14.75) 81.14 (8.88) 
Riccardi Scale 
1 
2 
3 
4 
 
7 (23.3%) 
17 (56.7%) 
4 (13.3%) 
2 6.7%) 
 
3 (18.8%) 
12 (75%) 
0 (0.0%) 
1(6.3%) 
 
4 (28.6%) 
5 (35.7%) 
4 (28.6%) 
1 (7.1%) 
Mutation status for 1 participant in placebo group unknown as participant was adopted 
†1 observation missing for Aberrant Behaviour Checklist and Conners: N=29 overall, N=15 in Group 
A. ADOS, Autism Diagnostic Observation Scale.  SRS T score >75 = autism symptoms within clinical 
range; ADOS total score >7 = meets diagnostic threshold for autism spectrum disorder. 
High scores on WASI indicate better performance. High scores on SRS, ADI-R, ADOS, ABC and 
Conners are indicative of higher levels of impairment. Parent defined target symptoms- frequency of 
the problem as rated by the parent.  
 
 
 
Table S3: Baseline clinical findings  
 
 Week 0 (N=30) Placebo (N=16) Simvastatin 
(N=14) 
ABC†    
Irritability 21.72 (10.03) 19.40 (10.38) 24.21 (9.36) 
Lethargy 15.07 (7.62)* 14.20 (8.36) 16.08 (6.85)* 
Stereotypy 6.03 (4.44) 4.87 (3.56) 7.29 (5.04) 
Hyperactivity 27.03 (11.42) 24.07 (13.04) 30.21 (8.75) 
Inappropriate 
speech 
6.66 (3.40) 5.93 (3.15) 7.43 (3.61) 
    
Conners†    
Inattention 80.21 (10.70) 79.73 (12.13) 80.71 (9.36) 
Hyperactivity 76.34 (12.95) 71.87 (14.75) 81.14 (8.88) 
Learning problems 72.66 (12.78) 68.53 (10.78) 77.07 (13.63) 
Executive function 76.66 (11.29) 74.40 (12.15) 79.07 (10.16) 
Aggression 72.17 (17.85) 69.87 (17.92) 74.64 (18.10) 
Peer relations 85.28 (9.62) 83.53 (11.36) 87.14 (7.27) 
    
CGI    
Severity of illness 
(mean (SD) 
3.73(0.785) 3.88 (0.885) 3.57(0.646) 
†1 observation missing for ABC and Conners: N=29 overall, N=15 in Group A  
*1 additional observation missing  
Higher scores on ABC, Conners & CGI are indicative of higher levels of impairment 
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Table S4 Adverse events  
Adverse events by body system Simvastatin Placebo 
 Grade 1-
2 
Grade 3 Grade 1-
2 
Grade 3 
Gastrointestinal system disorders 1 (1) 0 4 (4) 2 (2) 
General, whole body system 
disorders 
1 (1) 0 2 (2) 0 
Neurologic system disorders 6 (5) 1 (1) 12 (4) 1 (1) 
Musculoskeletal system disorders 4 (2) 0 4 (4) 1 (1) 
Respiratory system disorders 2 (1) 0 4 (4) 2 (2) 
Cardiovascular system disorders 0 0 0 0 
Psychiatric disorders 7 (7) 2 13 (5) 4 (3) 
Visual system disorders 0 0 0 0 
Dermatologic system disorders 3 (3) 2 (2) 6 (4) 1 (1) 
Urinary system disorders 0 0 1 (1) 0 
     
 No of events (no of patients who reported the event) 
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Table S5 Week 4 intermediate outcomes 
Week 4 outcomes Summary statistics Mean difference 
 Sample  Placebo 
 
Simvastatin 
 
Adjusted mean 
difference (95% 
CI) 
Bootstra
p SE 
Effect Size 
(95% CI) 
Number 
in 
analysis 
ABC N=29 N=16 N=13     
Irritability* 18.89 
(10.02) 
17.06 (9.90) 21.33(10.08)* 0.93 (-3.95, 5.82) 2.49 0.09 (-0.39, 
0.58) 
27 
Lethargy* 12.46 (8.95) 11.56 (9.19) 13.67 (8.86) * 0.66 (-5.58, 6.91) 3.19 0.07 (-0.62, 
0.77) 
26 
Stereotypy* 6.00 (4.78) 5.06 (4.36) 7.25 (5.21) * 0.42 (-2.21, 3.04) 1.34 0.09 (-0.46, 
0.64) 
27 
Hyperactivity 24.41 
(12.74) 
21.25 (12.82) 28.31 (11.97) 0.66 (-4.16, 5.48) 2.46 0.05 (-0.33, 
0.43) 
28 
Inappropriate 
speech 
5.69 (3.08) 5.06 (2.82) 6.46 (3.33) 0.52 (-0.88, 1.92) 0.71 0.17 (-0.29, 
0.62) 
28 
25% reduction 
irritability subscale 
N=12 7 5     
Conners N=26 N=16 N=10     
Inattention 76.88 
(12.91) 
75.94 (12.97) 78.40 (13.36) 2.65 (-2.85, 8.16) 2.81 0.21 (-0.22, 
0.63) 
25 
Hyperactivity 73.04 
(16.00) 
70.31 (17.78) 77.40 (12.22) -2.67 (-9.02, 3.69) 3.24 -0.17 (-0.56, 
0.23) 
25 
Learning problems 68.38 
(14.17) 
64.63 (11.19) 74.40 (16.83) 3.19 (-1.76, 8.15) 2.53 0.23 (-0.12, 
0.58)  
25 
Executive function 74.19 
(15.66) 
72.13 (17.55) 77.50 (12.17) -1.05 (-9.22, 7.12) 4.17 -0.07 (-0.59, 
0.45) 
25 
Aggression 71.04 
(19.22) 
72.44 (19.67) 68.80 (19.29) -4.43 (-14.98, 
6.11) 
5.38 -0.23 (-0.78, 
0.32) 
25 
Peer relations 84.58 
(11.06) 
83.44 (12.23) 86.40 (9.19) 1.10 (-3.15, 5.35) 2.17 0.10 (-0.28, 
0.48) 
25 
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Parent defined 
target symptoms 
(PDTS) 
N=29 N= 16 N=13     
Mean (SD) 4.38(1.179) 4.46 (0.718) 4.28 (1.577)     
Responders  (PDTS 
score <3) 
3 2 1     
CGI* N=29 N=16 N=13     
Severity of illness 
Mean (SD) 
3.69(0.712) 3.69 (0.793) 3.69(0.630)     
Treatment 
responder 
N=1 N=1 N=0     
*1 additional observation missing. Treatment responder defined as >25% reduction in ABC Irritability sub-scale and a score of improved or much improved 
on CGI. High scores on ABC, Conner’s, CGI & PDTS are indicative of higher levels of impairment. 
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Table S6: Quantification of MAPK outcomes at baseline and endpoint 
 
Participant 
number Group 
MAPKKinase
_Wk_0 
MAPKinase_ 
Wk_12 
S0001 Placebo 50.3114126 .2188209 
S0002 Placebo 2.9527485 4.8079458 
S0006 Placebo 3.8926110 61.8679608 
S0020 Placebo 27.5060898 142.9943580 
S0023 Placebo 3.0623875 42.2400651 
S0029 Placebo 63.7154251 70.4316268 
S0033 Placebo 96.9558036 
 S0034 Placebo 35.0355789 92.9567297 
S0035 Placebo 56.1097401 64.3669527 
S0036 Placebo 45.2664300 89.7891294 
S0037 Placebo 62.6400898 
 S0046 Placebo 10.9267266 48.8793436 
S0056 Placebo 15.7506385 31.6528862 
S0057 Placebo 119.4835133 376.8717635 
S0060 Placebo 167.6537279 56.7577496 
S0063 Placebo 
  S0005 Simvastatin 4.5859668 12.1169060 
S0010 Simvastatin 24.1460914 9.0388298 
S0011 Simvastatin 2.2530488 18.8252183 
S0021 Simvastatin 
  S0025 Simvastatin 4.5638149 85.4512618 
S0027 Simvastatin 54.9854703 
 S0031 Simvastatin 25.6439249 31.2619203 
S0038 Simvastatin 62.7051706 61.4602927 
S0039 Simvastatin 51.8592134 
 S0043 Simvastatin 355.4792373 47.5177311 
S0051 Simvastatin 
  S0058 Simvastatin 172.9821432 75.6083354 
S0061 Simvastatin 47.9587414 72.1282853 
S0062 Simvastatin 86.8384461 
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Table S7: A comparison of the mutation data in the SANTA sample to previously reported data from a clinic referred NF1 sample (see text) 
 
Study Ref Mutation Type Exon 
S0001 WGD large re EGD 
S0003 c.3911T>A p. (Leu 1 304Ter) nonsense exon 29 
S0005 c.2041C>T nonsense exon 18 
S0006* c.3741deIT frameshift exon 28 
S0010 c.3916C>T nonsense exon 29 
S0011 c.5749+332A>G splice intron 38 
S0020 c.3497-4T>G splice intron 26 
S0021 c.203delins6 frameshift exon 02 
S0023 c.2504_2505delAG frameshift exon 21 
S0025 c.2953C>T p.(Gln985Ter) nonsense exon 22 
S0027 c.174delC frameshift exon 02 
S0029** C.7908-321C>G  Splice deep 
intronic 
intron 54 
S0031 c.5546G>A p.(Arg1849G1n) missense exon 37 
S0033 c.4537C>T(p.Arg1513Ter) nonsense exon 35 
S0034 c.1246C>Tp.(Arg416Ter) nonsense exon 11 
S0035* c.3741delT frameshift exon 28 
S0036 c.7239_7240insTT frameshift exon 49 
S0037 c.1381C>Tp.(Arg461Te nonsense exon 12 
S0038 c.2087G>A p.(Trp696Ter) nonsense exon 18 
S0039 c.4306A>G p.(Lys1436GIu) missense exon 32 
S0043 c.1260+1G>A splice intron 11 
S0046** C.7908-321C>G  Splice deep 
intronic 
intron 54 
S0051  Not done     
S0056 c.479G>Tp.(Arg160Met)  missense intron 4 
S0057  C7404_7405insTA. Glu2469Ter  frameshift  Exon 51 
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S0058 c.7096_7101del6p.(Asn2366_Phe236
7del) 
in-frame 
deletion 
exon 48 
S0060 c.1756_1759delACTA frameshift exon 16 
S0061 c.1186-1G>T  splice Exon 11 
S0062 Not done     
S0063  Not done      
Data was not available for 3 participants  
* & ** sibling pairs 
 
  SANTA % Controls+ % 
splice 5 19.23% 80 22.99% 
frameshift 8 30.77% 114 32.76% 
nonsense 8 30.77% 76 21.84% 
missense 3 11.54% 31 8.91% 
large re 1 3.85% 28 8% 
ifd 1 3.85% 13 3.74% 
 26  342  
 + Evans et al European Journal of Human Genetics 2016 [22] 
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Figure S4 SANTA CONSORT flow diagram (see text; SRS, Social Responsiveness Scale) 
 
 
 
Ineligible on SRS (SRS T 
scores<59) N= 11 
Older than 10.5 years N=4 
On active exclusion treatment 
(see text)  N=3 
Not NF1 n=2 
 
Met eligibility criteria 
N= 71 
DNA in-depth assessment n=7 
Not interested N=11 
In-depth ASD 
assessments 
N=53 
Did not meet research ASD 
criteria N=19 
Met research ASD 
criteria N=34 
Consent withdrawn before 
randomisation N=2 
Not NF1 diagnosis N=2 
 
Placebo  
N=16 
Simvastatin 
N= 14                                 
Screened on SRS   
N= 91 
Completed 3 trial 
visits 
N=11 
Completed 3 trial 
visits N=15 
DNA week 12 
assessment N=1 
Consent withdrawn after 
baseline visit N=1 
DNA week 12 assessment 
N=2 
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